$RNAC

Cartesian Therapeutics, Inc. (RNAC): Submission of Matters to a Vote of Security Holders

Cartesian Therapeutics, Inc. (RNAC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. rnac-20260612 0001453687 false 0001453687 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Original reporting
Published Jun 17, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$RNAC
Neutral
high confidence
Mentioned
$RNAC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RNACNeutralLow
01

Why it matters

The disclosure confirms director elections, advisory executive compensation approval, and ratification of Ernst & Young LLP as auditor for 2026, but does not introduce new financial targets, clinical updates, or corporate actions.

02

Market read

Primarily a compliance/governance recap; not a catalyst for valuation changes on its own.

03

What to watch

Traders may still watch for follow-on disclosures (e.g., post-meeting board actions, committee assignments) that are not included in this 8-K.

Relevance 6/10Novelty 2/10Timing: Filed June 17, 2026 after June 12 annual meeting

Background

The filing is an SEC Form 8-K (Item 5.07) summarizing matters voted on at the company’s June 12, 2026 annual meeting.

Company-level read

Ticker impact

$RNACNeutralHigh confidence
Context

Cartesian Therapeutics reported 2026 annual meeting voting results, including election of three Class I directors and advisory say-on-pay approval.

Expected impact

Likely limited near-term impact; any move would be sentiment/flow-driven rather than fundamentals.

Evidence & confidence

The 8-K item is a recap of shareholder votes (director election, say-on-pay, auditor ratification) with no new strategy, financing, or regulatory/clinical catalyst.

Market effects

Minimal; governance mechanics typically do not change biotech sector risk premia.

Minimal; Nasdaq-listed issuer-specific filing.

Minimal; no cross-border transaction or regulatory action described.

Counterpoint

If the market had been pricing governance uncertainty, director election outcomes could reduce overhang—but the filing provides no contested outcome or proxy fight details.

Key entities

  • Cartesian Therapeutics, Inc.

    Nasdaq-listed issuer that held the annual meeting and reported voting results on directors, say-on-pay, and auditor ratification.

  • Ernst & Young LLP

    Ratified by stockholders as independent registered public accounting firm for the year ending December 31, 2026.

Related articles

$RNACHighAI 8/10

Cartesian Reports Positive Phase 2 Retreatment Data For Descartes-08

Cartesian Therapeutics (RNAC) reported Phase 2 retreatment data for Descartes-08 in generalized myasthenia gravis, showing sustained symptom improvements 12 months post-retreatment. The study involved five patients, with mean MG-ADL and MGC scores decreasing by 6.6 and 15 points, respectively. The company plans to report Phase 3 results in Q1 2027 and submit a BLA in mid-2027. RNAC stock closed at $7.21, down 2.70%.

$RNACHighAI 9/10

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

Cartesian Therapeutics, Inc. (RNAC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retre

$RNACMedAI 8/10

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

Cartesian Therapeutics (RNAC) reported additional retreatment data for Descartes-08, showing a mean MG-ADL reduction of 6.6 points at Month 12. The median interval between initial treatment and retreatment was 16.6 months. No new safety signals were reported. Topline Phase 3 AURORA trial data is expected in 1Q27.

$RNACMed

Cartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 2026 results and a business update. Phase 3 AURORA for Descartes-08 in myasthenia gravis continues, with data expected in 1Q27 and a BLA planned for mid-2027. Phase 2 TRITON myositis and Phase 1/2 HELIOS pediatric trials remain on track for 1H27 data. Cash was $149.3M at June 30, 2026, supporting operations into 2028.

$RNACMed

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics, Inc. (RNAC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-20

$RNACMed

Why Is Cartesian Therapeutics Stock Trading Higher Today? - Cartesian Therapeutics (NASDAQ:RNAC)

Cartesian Therapeutics (NASDAQ:RNAC) rose after licensing its in vivo CAR-T platform to WestGene, with an upfront payment and potential development/commercial milestones, the company said. The partnership targets a myasthenia gravis trial in 2H 2026 and data in 1H 2027. Shares were about $6.90, up 17.75% Tuesday, per Benzinga Pro. Analysts rate Buy with an average $29.75 target.